Podcasts

Pharmaceutical Executive Daily

FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.

Pharmaceutical Executive Daily

FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

Pharmaceutical Executive Daily

How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.

Pharmaceutical Executive daily

FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.

Sponsored

Two teams can size the same market using the exact same healthcare claims data and land millions of patients apart. The data is identical, but the cohort definition is not, and almost nobody checks the range. While real-world data can map treatment flows, disease progression, outcomes, and cost of care across payers, every insight rests on a definition that usually goes untested and may not even be published at all. In this episode, Scott L. DuVall, PhD, SVP of Real-World Evidence at PurpleLab, whose CARES initiative puts high-precision data and methods behind real-world research, explains which definitional choices move a result, what to ask before building on numbers you didn't produce, and the four requirements he would insist on for every study.

Pharmaceutical Executive Daily

The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.